Epilepsy Research
Volume 31, Issue 1 , Pages 59-71 , June 1998

Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man

Received 3 November 1997 ,Revised 24 February 1998 ,Accepted 3 March 1998.

References 

  1. Fagg GE, Olpe HR, Pozza MF, Baud J, Steinmann M, Schmutz M, et al. CGP 37849 and CGP 39551: novel and potent competitive N-methyl-d-aspartate receptor antagonists with oral activity. Br. J. Pharmacol. 1990;99:791–797
  2. Goddard GV, McIntyre DC, Leech CK. A permanent change in brain function resulting from daily electrical stimulation. Exp. Neurol. 1969;25:295–330
  3. Grant SM, Heel RC. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs. 1991;41:889–926
  4. Hönack D, Löscher W. Kindling increases the sensitivity of rats to adverse effects of certain antiepileptic drugs. Epilepsia. 1995;36(8):763–771
  5. Irwin S. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia (Berl.). 1968;13:222–257
  6. Kupferberg HJ. Antiepileptic drug development program: a cooperative effort of government and industry. Epilepsia. 1989;30(Suppl. 1):S51–S56
  7. Löscher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 1988;2:145–181
  8. Löscher W, Hönack D. Anticonvulsant and behavioural effects of two novel competitive N-methyl-d-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine. J. Pharmacol. Exp. Ther. 1991;256:432–440
  9. Löscher W, Schmidt D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation?. Epilepsy Res. 1994;17:95–134
  10. Löscher W, Jäckel R, Czuczwar SJ. Is amygdala kindling in rats a model for drug-resistant partial epilepsy?. Exp. Neurol. 1986;93:211–226
  11. McNamara JO, Russell RD, Rigsbee L, Bonhaus DW. Anticonvulsant and antiepileptogenic actions of MK-801 in the kindling and electroshock models. Neuropharmacology. 1988;27(6):563–568
  12. Nevins ME, Arnolde SM. A comparison of the anticonvulsant effects of competitive and non-competitive antagonists of the N-methyl-d-aspartate receptor. Brain Res. 1989;503:1–4
  13. Paxinos, G., Watson, C., 1982. The Rat Brain in Stereotaxic Coordinates. Academic Press, Australia.
  14. Porter, R.J., 1986. Antiepileptic drugs: efficacy and inadequacy. In: Meldrum, B.S., Porter, R.J. (Eds.), New Anticonvulsant Drugs. John Libbey, London, pp. 3–17.
  15. Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroenceph. Clin. Neurophysiol. 1972;32:295–299
  16. Sangdee P, Turkanis SA, Karler R. Kindling-like effect induced by repeated corneal electroshock in mice. Epilepsia. 1982;23:471–479
  17. Shorvon SD. Comparative evidence on efficacy and safety of different dosages of levetiracetam in add-on treatment of partial epilepsy. Epilepsia. 1997;38(Suppl. 3):78
  18. Sveinsbjornsdottir S, Sander JWAS, Upton D, Thompson PJ, Patsalos PN, Hirt D, et al. The excitatory amino acid antagonist D-CPPene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res. 1993;16:165–174
  19. Swinyard EA, Wolf HH, White HS, Skeen GA, Stark LG, Albertson T, et al. Characterization of the anticonvulsant properties of F-721. Epilepsy Res. 1993;15:35–45
  20. White, H.S., Woodhead, J.H., Franklin, M.R., Swinyard, E.A., Wolf, H.H., 1995. General principles — experimental selection, quantification and evaluation of antiepileptic drugs. In: Levy, R.H., Mattson, R.H., Meldrum, B.S. (Eds.), Antiepileptic Drugs, 4th ed. Raven Press, New York, pp. 99–110.

PII: S0920-1211(98)00016-3

Epilepsy Research
Volume 31, Issue 1 , Pages 59-71 , June 1998

Article Tools

* Image Usage & Resolution